BridgeBio Awards Equity to 11 New Employees
BridgeBio Pharma, Inc. has awarded equity to 11 new employees, totalling 23,884 shares of common stock. The grants were made under the company's Amended and Restated 2019 Inducement Equity Plan, approved by the compensation committee on October 2, 2025.
The vesting schedule for these shares is as follows: one-fourth will vest on November 16, 2026, with the remaining shares vesting quarterly over the next three years, contingent upon continued employment.
As of October 2025, the identity of BridgeBio's chairman of the executive board (CEO or equivalent) remains unspecified in available search results. The company's compensation structure in October 2025 does not mention share-based inducement grants, unlike Intellia Therapeutics, which has such information available.
BridgeBio Pharma, Inc. has welcomed 11 new employees, rewarding them with equity as part of the company's inducement plan. The vesting schedule is designed to encourage long-term commitment and performance. The company's executive leadership and compensation structure continue to evolve, with details subject to updates.
Read also:
- HLC Approves ₹4,645.60 Crore for Flood Recovery and Wetland Rejuvenation in Nine States
- Crooked House Pub's Demolition: Council Orders Rebuild, Debate on Historic Building Protections
- Shaping India's Economic Progression: Readying the Financial System for Tomorrow
- Conflict between Ben & Jerry's co-founder and Unilever over Gaza issues leads to resignation of co-founder
